Unknown

Dataset Information

0

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination.


ABSTRACT: CCNE1 amplification is a common alteration in high-grade serous ovarian cancer and occurs in 15-20% of these tumors. These amplifications are mutually exclusive with homologous recombination deficiency, and, as they have intact homologous recombination, are intrinsically resistant to poly (ADP-ribose) polymerase inhibitors or chemotherapy agents. Understanding the molecular mechanisms that lead to this mutual exclusivity may reveal therapeutic vulnerabilities that could be leveraged in the clinic in this still underserved patient population. Here, we demonstrate that CCNE1-amplified high-grade serous ovarian cancer cells rely on homologous recombination to repair collapsed replication forks. Cyclin-dependent kinase 2, the canonical partner of cyclin E1, uniquely regulates homologous recombination in this genetic context, and as such cyclin-dependent kinase 2 inhibition synergizes with DNA damaging agents in vitro and in vivo. We demonstrate that combining a selective cyclin-dependent kinase 2 inhibitor with a DNA damaging agent could be a powerful tool in the clinic for high-grade serous ovarian cancer.

SUBMITTER: Brown VE 

PROVIDER: S-EPMC10373114 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

CDK2 regulates collapsed replication fork repair in CCNE1-amplified ovarian cancer cells via homologous recombination.

Brown Victoria E VE   Moore Sydney L SL   Chen Maxine M   House Nealia N   Ramsden Philip P   Wu Hsin-Jung HJ   Ribich Scott S   Grassian Alexandra R AR   Choi Yoon Jong YJ  

NAR cancer 20230727 3


<i>CCNE1</i> amplification is a common alteration in high-grade serous ovarian cancer and occurs in 15-20% of these tumors. These amplifications are mutually exclusive with homologous recombination deficiency, and, as they have intact homologous recombination, are intrinsically resistant to poly (ADP-ribose) polymerase inhibitors or chemotherapy agents. Understanding the molecular mechanisms that lead to this mutual exclusivity may reveal therapeutic vulnerabilities that could be leveraged in th  ...[more]

Similar Datasets

| S-EPMC6155164 | biostudies-literature
| S-EPMC4030885 | biostudies-literature
| S-EPMC6126713 | biostudies-literature
| S-EPMC10253825 | biostudies-literature
| S-EPMC7332989 | biostudies-literature
| S-EPMC5503685 | biostudies-literature
| S-EPMC8082280 | biostudies-literature
| S-SCDT-EMBOR-2019-49367V1 | biostudies-other
| S-EPMC6316604 | biostudies-literature
| S-EPMC3896206 | biostudies-literature